Epigenetic drugs and epigenetic therapies

Dear Colleagues,

Many diseases (e.g., cancer, diabetes, heart, mental, and autoimmune diseases) are associated with epigenetic aberrations including DNA methylation, histone post-translational modifications, chromatin remodeling, and regulatory RNA. Until now, the DNMT inhibitors 5-azacytidine and 5-aza-20-deoxycytidine and the HDAC inhibitors belinostat, panobinostat, romidepsin, vorinostat have been approved by the FDA for the treatment of various cancers. Many of these drugs suffer from high toxicity, rapid metabolism, poor bioavailability, and limited effectiveness in monotherapy. However, in combinatorial therapy, they can be beneficial to patients. In this Special Issue, we would like to invite the submission of manuscripts containing new findings, which may contribute to the design and use of new epigenetic drugs with improved activity, functional significance of different epigenetic drugs (or candidates)-induced signaling pathways and their clinical implications, improvement of the new drugs selectivity, identification of new molecular targets of epigenetic drugs and their clinical significance, and potential combined epigenetic therapies.

We look forward to your contributions.

Dr. Marcin Ratajewski
Guest Editor

More information: https://www.mdpi.com/journal/pharmaceuticals/special_issues/Epigenetic_Drugs


Appeal for the creation of separate ministries of Science and Higher Education and National Education

The Polish Academy of Sciences, the General Council of Science and Higher Education and the Foundation for Polish Science appealed for the creation of two separate ministries: science and Higher…

see more
MINIATURA 7 Competition

As part of the Miniatura 7 competition, the National Science Center awarded funds to Dr. Joanna Pastwińska for the implementation of scientific activities entitled “The role of the interleukin IL17B…

see more